Evidence map›Paper›PMID 22570487›Full record

ArticleThe Journal of biological chemistry2012

High throughput screening for compounds that alter muscle cell glycosylation identifies new role for N-glycans in regulating sarcolemmal protein abundance and laminin binding.

Paula V Cabrera, Mabel Pang, Jamie L Marshall, Raymond Kung, Stanley F Nelson, Stephanie H Stalnaker, Lance Wells, Rachelle H Crosbie-Watson, Linda G Baum

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Paula V CabreraDepartment of Pathology and Laboratory Medicine, UCLA School of Medicine, Los Angeles, California 90095, USA.
Mabel Pang
Jamie L Marshall
Raymond Kung
Stanley F Nelson
Stephanie H Stalnaker
Lance Wells
Rachelle H Crosbie-Watson
Linda G Baum
University of California, Los Angeles · USUniversity of Georgia · US

Funding

TR&D1: Stem Cell and Induced Pluripotent Stem Cell Resources (Pages 116-134)P41GM103490 · NIGMS · UNIVERSITY OF GEORGIA · PI PIERCE, J. MICHAEL · 2012 to 2018
$13.7M
Structure-Function Analysis of SarcospanR01AR048179 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CROSBIE, RACHELLE HOPE · 2001 to 2023
$6.9M
UCLA Muscular Dystrophy Core CenterP30AR057230 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SPENCER, MELISSA JAN · 2009 to 2018
$6.2M
PREDOCTORAL TRAINING PROGRAM IN GENETIC MECHANISMS AT UCT32GM007104 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GOBER, JAMES W · 1985 to 2011
$3.6M
NIAMS NIH HHS P30 AR057230NIAMS NIH HHS R01 AR048179NIGMS NIH HHS P41 GM103490NIGMS NIH HHS T32 GM007104NIGMS NIH HHS T32 GM07104
6 · The paper itself

Abstract

Duchenne muscular dystrophy is an X-linked disorder characterized by loss of dystrophin, a cytoskeletal protein that connects the actin cytoskeleton in skeletal muscle cells to extracellular matrix. Dystrophin binds to the cytoplasmic domain of the transmembrane glycoprotein β-dystroglycan (β-DG), which associates with cell surface α-dystroglycan (α-DG) that binds laminin in the extracellular matrix. β-DG can also associate with utrophin, and this differential association correlates with specific glycosylation changes on α-DG. Genetic modification of α-DG glycosylation can promote utrophin binding and rescue dystrophic phenotypes in mouse dystrophy models. We used high throughput screening with the plant lectin Wisteria floribunda agglutinin (WFA) to identify compounds that altered muscle cell surface glycosylation, with the goal of finding compounds that increase abundance of α-DG and associated sarcolemmal glycoproteins, increase utrophin usage, and increase laminin binding. We identified one compound, lobeline, from the Prestwick library of Food and Drug Administration-approved compounds that fulfilled these criteria, increasing WFA binding to C2C12 cells and to primary muscle cells from wild type and mdx mice. WFA binding and enhancement by lobeline required complex N-glycans but not O-mannose glycans that bind laminin. However, inhibiting complex N-glycan processing reduced laminin binding to muscle cell glycoproteins, although O-mannosylation was intact. Glycan analysis demonstrated a general increase in N-glycans on lobeline-treated cells rather than specific alterations in cell surface glycosylation, consistent with increased abundance of multiple sarcolemmal glycoproteins. This demonstrates the feasibility of high throughput screening with plant lectins to identify compounds that alter muscle cell glycosylation and identifies a novel role for N-glycans in regulating muscle cell function.

Indexed as

AnimalsCells, CulturedGlycomicsGlycosylationLamininLobelineMaleMannosyltransferasesMiceMice, Inbred mdxMuscle Fibers, SkeletalMuscle ProteinsMuscular Dystrophy, DuchenneMyoblasts, SkeletalNicotinic AgonistsPlant LectinsLamininLobelineMannosyltransferasesMuscle ProteinsNicotinic AgonistsPlant LectinsPolysaccharidesReceptors, N-AcetylglucosamineRNA, Small Interferingwisteria lectin

Identifiers

PMID22570487
PMCPMC3391114
OpenAlexW2018140672

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.